Novartis and Novo Nordisk partner to commercialize novel insulin sensitizer (NN622) in North America
20-Jul-2001 -
Novartis Pharma AG and Novo Nordisk today announced an agreement on the commercialization of NN622,
currently in development for the treatment of type 2 diabetes. Under the terms of the agreement Novartis acquires exclusive rights to commercialize the
compound in the US, Canada and Mexico, with ...
cardiovascular diseases
clinical trials
glucose
+3